165 related articles for article (PubMed ID: 24684645)
21. Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.
Samanta D
Epilepsy Behav; 2021 Jan; 114(Pt A):107612. PubMed ID: 33243685
[TBL] [Abstract][Full Text] [Related]
22. Clobazam : in patients with Lennox-Gastaut syndrome.
Yang LP; Scott LJ
CNS Drugs; 2012 Nov; 26(11):983-91. PubMed ID: 23034582
[TBL] [Abstract][Full Text] [Related]
23. The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis.
Reaven NL; Funk SE; Lyons PD; Story TJ
Epilepsy Behav; 2019 Apr; 93():65-72. PubMed ID: 30831405
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1563-1574. PubMed ID: 31373526
[No Abstract] [Full Text] [Related]
25. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
Nikanorova M; Brandt C; Auvin S; McMurray R
Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
[TBL] [Abstract][Full Text] [Related]
26. The pharmacological management of Lennox-Gastaut syndrome and critical literature review.
Verrotti A; Striano P; Iapadre G; Zagaroli L; Bonanni P; Coppola G; Elia M; Mecarelli O; Franzoni E; Liso P; Vigevano F; Curatolo P
Seizure; 2018 Dec; 63():17-25. PubMed ID: 30391662
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
Verdian L; Yi Y
Seizure; 2010 Jan; 19(1):1-11. PubMed ID: 19942457
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
Bergmann KR; Broekhuizen K; Groeneveld GJ
Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study.
Weinstock A; Agarwal N; Farooq O; Cheema Z; Hamilton D; Parrish J
J Child Neurol; 2019 Jul; 34(8):432-439. PubMed ID: 30913948
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome.
Montouris GD; Wheless JW; Glauser TA
Epilepsia; 2014 Sep; 55 Suppl 4():10-20. PubMed ID: 25284033
[TBL] [Abstract][Full Text] [Related]
32. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Kanner AM; Ashman E; Gloss D; Harden C; Bourgeois B; Bautista JF; Abou-Khalil B; Burakgazi-Dalkilic E; Llanas Park E; Stern J; Hirtz D; Nespeca M; Gidal B; Faught E; French J
Neurology; 2018 Jul; 91(2):82-90. PubMed ID: 29898974
[TBL] [Abstract][Full Text] [Related]
33. Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion.
Sankar R; Chez M; Pina-Garza JE; Dixon-Salazar T; Flamini JR; Hyslop A; McGoldrick P; Millichap JJ; Resnick T; Rho JM; Wolf S
Seizure; 2023 Aug; 110():42-57. PubMed ID: 37321047
[TBL] [Abstract][Full Text] [Related]
34. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis.
Devi N; Madaan P; Ameen R; Sahu JK; Bansal D
Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis.
Zhang L; Wang J; Wang C
Dev Med Child Neurol; 2022 Mar; 64(3):305-313. PubMed ID: 34590711
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome.
Faulkner MA
Ther Clin Risk Manag; 2015; 11():905-14. PubMed ID: 26089675
[TBL] [Abstract][Full Text] [Related]
37. Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.
Purcarin G; Ng YT
Ther Adv Neurol Disord; 2014 May; 7(3):169-76. PubMed ID: 24790647
[TBL] [Abstract][Full Text] [Related]
38. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Supratherapeutic Doses of Clobazam.
Gedela S; Freedman DA; Gedela S; Glynn P; Salvator A; Patel AD
J Child Neurol; 2019 Oct; 34(12):735-738. PubMed ID: 31215313
[TBL] [Abstract][Full Text] [Related]
40. Lennox-Gastaut syndrome: New treatments and treatments under investigation.
Auvin S
Rev Neurol (Paris); 2020 Jun; 176(6):444-447. PubMed ID: 32409177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
